Zacks Research Issues Optimistic Estimate for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Investment analysts at Zacks Research upped their FY2024 earnings per share estimates for shares of Teva Pharmaceutical Industries in a report released on Monday, November 4th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.30 per share for the year, up from their previous estimate of $2.29. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2024 earnings at $0.67 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $2.77 EPS.

Several other equities analysts also recently issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Barclays upped their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Wednesday, July 10th. Finally, UBS Group upped their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $17.43 on Thursday. Teva Pharmaceutical Industries has a 1 year low of $8.55 and a 1 year high of $19.31. The stock has a market cap of $19.75 billion, a PE ratio of -44.69, a P/E/G ratio of 1.34 and a beta of 0.87. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The stock’s 50 day simple moving average is $18.00 and its 200-day simple moving average is $17.06.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of the company. New Covenant Trust Company N.A. bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $28,000. EntryPoint Capital LLC bought a new stake in Teva Pharmaceutical Industries during the 1st quarter worth approximately $30,000. UMB Bank n.a. lifted its stake in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA bought a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at $48,000. Finally, Byrne Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $52,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.